Ultragenyx Pharmaceutical Inc. reported on March 12, 2026, that its DTX301 gene therapy for OTC deficiency showed an 18% reduction in plasma ammonia levels in treated patients compared to placebo, with 71% of patients experiencing significant symptom improvement. The therapy was well tolerated, with ongoing studies and further data anticipated in 2027.